The toxic threshold concentration (TTC, μM) values for Sunitinib and Imatinib are swapped in [Fig 1B](#pone.0208342.g001){ref-type="fig"}. The toxic threshold concentration for Sunitinib is 1.88 μM and the toxic threshold concentration for Imatinib is 18.99 μM. The safety margin (TTC/TPC) values for Sunitinib and Imatinib are also incorrect. The correct safety margin for Sunitinib is 9.4 and the correct safety margin for Imatinib is 9.4. Please see the correct [Fig 1](#pone.0208342.g001){ref-type="fig"} here.

![TKI effect on EHT contractility.\
(A) Depiction of concentration-effect curves (curve-fitted) of 9 TKIs after 96 hours of TKI incubation (▲), normalized to vehicle control (Δ). The toxic threshold (black dashed line) is defined as a decline in contractile force of \>40% vs. baseline (BL). Mean values ± SEM; n = 4; \*p\<0.05 vs. baseline, two-way ANOVA and Bonferroni's multiple comparison post-test. (B) Total therapeutic plasma concentration (TPC), toxic threshold concentration (TTC: TKI concentration leading to ≥40% reduction in EHT contractile force) and safety margin (SM: TTC/TPC), n/a: not applicable.](pone.0208342.g001){#pone.0208342.g001}

The toxic threshold concentration and safety margin values for Sunitinib and Imatinib are also incorrect in [S1 Table](#pone.0208342.s001){ref-type="supplementary-material"}. Please see the correct [S1 Table](#pone.0208342.s001){ref-type="supplementary-material"} below.
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